A Randomized, Double-Blind, Placebo Controlled Study of NPC-02 in Patients With Zinc Deficiency

Exclusion Criteria

• •1. Heavy hepatitis
• •2. Malignant tumor
• •3. Severe heart disease, hematological disorder, kidney disease and pancreatic disease, etc.
• •4. The serum albumin under 2.8 g/dL
• •5. Patient of allergy and hyperesthesia to zinc containing medicine manufacturing (including supplement)
• •6. Patient who was taking a medicine including the zinc (including supplement) within 12 weeks before registration
• •7. Pregnant, suspected pregnant, lactating, patients who wish to have a child
• •8. Patient who participated in other clinical trials within 12 weeks before registration
• •9. Unsuitable as a target of this clinical trial judged by doctor